ArticleActa diabetologica2026
A multicenter prospective evaluation of the benefits of Dexcom ONE + in subjects with type 2 diabetes on insulin therapy beyond glycemic control: results from the LIFE-ONE study.
Article in Acta diabetologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsContinuous glucose monitoring (CGM) has demonstrated to improve glucose control in people with type 2 diabetes (T2D) especially in those on insulin therapy. Dexcom ONE + is a CGM system with some particular features, however, there is no clinical study conducted with this device. The aim was to determine whether Dexcom ONE + can improve glucose control and patient-reported outcomes in insulin-treated T2D subjects.
methodsProspective, multicenter study including T2D on multiple insulin injections (MDI) or basal insulin (BI), without CGM experience and HbA1c > 7% (53 mmol/l). They used blinded Dexcom ONE + for 10 days and in open mode for 12 weeks. HbA1c, CGM-metrics, quality of life, fear and awareness of hypoglycemia were obtained baseline and at 12-weeks, and treatment satisfaction at 12 weeks.
results159 subjects completed the study (MDI 75, BI 84). HbA1c decreased in MDI group from 8.18 ± 1.3% (65.9 ± 3.3 mmol/mol) to 7.34 ± 0.8% (56.7 ± 2.1 mmol/mol) and in BI group from 8.13 ± 1.3% (65 ± 3.3 mmol/mol) to 7.32 ± 0.7% (56.5 ± 1.9 mmol/mol) (p < 0.01). TIR increased in MDI group from 52.1 ± 25% to 60.7 ± 22% (p = 0.011) and in BI group from 58.8 ± 22% to 65.8 ± 19% (p = 0.0015). High degree of satisfaction and improvement in quality of life were observed in both groups and lower fear of hypoglycemia in BI group.
conclusionsIn this first clinical study, Dexcom ONE + enhanced glycemic control and improve patient-reported outcomes with high satisfaction.
Indexed as
Identifiers
41964691What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.